[2P] Poster Presentation 2

[2P-847] HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for overcoming drug resistance in EGFR-mutant lung cancer.

○Akihiko Ishimura¹, Hanbing Lyu¹, Ryusuke Suzuki¹, Khurelsukh Buyanbat¹, Gerelsuren Batbayar², Makiko Meguro-Horike³, Shin-ichi Horike³, Hidekazu Tsutsui ⁴, Seiji Yano⁵, Takeshi Suzuki¹ (1. Cancer Res. Inst., Kanazawa univ., 2. Inst. Biol., Mongolian Academy of Sci., 3. Inst. Liberal Art and Sci., Kanazawa univ., 4. School of Materials Sci., Japan Advanced Inst. Sci. and Tech., 5. Dept. Respiratory Med., Fac. Med. Kanazawa univ.)